Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6536-6543

  Sperr, Wolfgang R ^a   Mitterbauer, Margit ^a   Mitterbauer, Gerlinde ^a   Kundi, Michael ^a   Jäger, Ulrich ^a   Lechner, Klaus ^a   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; TRYPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BIOCHEMICAL REMISSION; BLAST CELL; DISEASE MARKER; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REFERENCE VALUE; RELAPSE; REMISSION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS; TIME FACTORS; TRYPTASES;

EID: 25144445759     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0732     Document Type: Article

References (37)

1. Vellenga E, Griffin JD. The biology of acute myeloid leukemia. Semin Oncol 1987;14:365-71.
2. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
3. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-33.
4. Strout MP, Marcucci G, Caligiuri MA, Bloomfield CD. Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol 1999;78:251-64.
5. Baer MR, Bloomfield CD. Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst 1991;83:663-5.
6. Marucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000;18:768-80.
7. Appelbaum FR. Molecular diagnosis and clinical decisions in adult acute leukemia. Semin Hematol 1999;36:401-10.
8. Hiddemann W, Büchner T Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol 2001;38:3-9.
9. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer 2001;92:1059-73.
10. Estey EH. Prognostic factors in acute myelogenous leukemia. Leukemia 2001;15:670-2.
11. Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 2001;40:231-52.
12. Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948-52.
13. Biondi A, Rambaldi A. Molecular diagnosis and monitoring of acute myeloid leukemia. Leuk Res 1996;20:801-7.
14. Buonamici S, Ottaviani E, Testoni N, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002;99:443-9.
15. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999;94:2225-9.
16. Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 witht(8;21). Blood 1996;88:3704-9.
17. Laczika K, Novak M, Hilgarth B, et al. Competitive CBFβ|VMYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion (16): a pilot study. J Clin Oncol 1998;16:1519-25.
18. Korninger L, Knöbl P, Laczika K, et al. PML-RAR α PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months. BrJ Haematol 1994;88:427-31.
19. Satake N, Maseki N, Kozu T, et al. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t (8;21) in long-term remission. Br J Haematol 1995;91:892-8.
20. Diverio D, Pandolfi PP, Biondi A, et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993;82:3556-9.
21. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-70.
22. San Miguel JF, Ciudad J, Vidriales MB, et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol 1999;32:175-85.
23. Basso G, Buldin B, De Zen L, Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Trends in Hematology 2001;86:675-92.
24. Bernell P, Arvidsson I, Jacobsson B, Hast R. Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukemia. Br J Haematol 1996;95:666-72.
25. Amare PS, Baisane C, Saikia T, Nair R, Gawade H, Advani S. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias. Cancer Genet Cytogenet 2001;131:125-34.
26. + cell sorting. Leukemia 2001;15:1408-14.
27. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98:2200-9.
28. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
29. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
30. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460-2.
31. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78:325-9.
32. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996;88:1390-8.
33. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8.
34. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994;14:190-204.
35. Therneau TM, Grambsch PM, Fleming TR. Martingale based residuals for survival models. Biometrika 1990;77:147-60.
36. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Mead 1987;316:1622-6.
37. Sperr WR, Walchshofer S, Horny HP, et al. Systemic mestocytosis associated with acute myeloid leukemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Brit J Haematol 1998;103:740-9.